IPP Bureau
Cupid invests in GII Healthcare Investment
By IPP Bureau - July 15, 2025
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
Merck launches AAW workstation to advance lab automation
By IPP Bureau - July 15, 2025
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
Sun Pharma launches LEQSELVI in US for treatment of severe alopecia areata
By IPP Bureau - July 14, 2025
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
By IPP Bureau - July 14, 2025
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Sun Pharma settles patent litigation with Incyte
By IPP Bureau - July 14, 2025
Merck to initiate Phase 3 trials for investigational once-monthly HIV prevention pill
By IPP Bureau - July 14, 2025
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Jubilant Ingrevia appoints Kailash Ukhade as VP – Projects
By IPP Bureau - July 14, 2025
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
Moderna receives USFDA approval for Covid-19 vaccine ‘Spikevax’
By IPP Bureau - July 13, 2025
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Evonik opens new medical device center in Shanghai
By IPP Bureau - July 12, 2025
The company’s largest center for medical device applications, serving the entire Asian market
DKSH and Bayer partner across multiple markets in Southeast Asia
By IPP Bureau - July 12, 2025
Panacea Biotec reaches settlement with Apotex
By IPP Bureau - July 12, 2025
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Hexaware and Abluva join forces to deliver secure Agentic AI solutions for life sciences industry
By IPP Bureau - July 12, 2025
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
Senores Pharmaceuticals to increase stake in Havix
By IPP Bureau - July 12, 2025
Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations
Briefs: Emcure Pharmaceuticals and Gland Pharma
By IPP Bureau - July 12, 2025
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Indegene launches NEXT Medical Writing Automation
By IPP Bureau - July 12, 2025
To streamline complex medical writing workflows with GenAI
